-+ 0.00%
-+ 0.00%
-+ 0.00%

Corbus enrolls last patient in Phase 1b CANYON-1 obesity trial of CRB-913

PUBT·04/14/2026 12:11:24
Listen to the news
Corbus enrolls last patient in Phase 1b CANYON-1 obesity trial of CRB-913
  • Corbus Pharmaceuticals reported last patient first visit in CANYON-1, a Phase 1b trial of oral obesity drug candidate CRB-913.
  • Study completion remains targeted for summer 2026, with results to be presented in the future.
  • Trial is designed to assess dose selection for a daily non-incretin therapy intended for weight loss and long-term weight management.
  • Corbus positioned CRB-913 as an alternative for patients who cannot tolerate or do not respond to incretin-based obesity drugs.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Corbus Pharmaceuticals Holdings Inc. published the original content used to generate this news brief on April 14, 2026, and is solely responsible for the information contained therein.